Farther Finance Advisors LLC Has $970,000 Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Farther Finance Advisors LLC increased its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,409 shares of the pharmaceutical company’s stock after acquiring an additional 107 shares during the quarter. Farther Finance Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $970,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Dunhill Financial LLC lifted its holdings in shares of Vertex Pharmaceuticals by 70.6% in the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 24 shares in the last quarter. Legacy Investment Solutions LLC bought a new position in Vertex Pharmaceuticals during the 3rd quarter valued at $33,000. Brown Lisle Cummings Inc. bought a new position in Vertex Pharmaceuticals during the 4th quarter valued at $30,000. Truvestments Capital LLC purchased a new position in Vertex Pharmaceuticals during the 3rd quarter worth $35,000. Finally, Sugar Maple Asset Management LLC bought a new stake in shares of Vertex Pharmaceuticals in the 4th quarter worth $35,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on VRTX. Jefferies Financial Group upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their price target for the stock from $500.00 to $550.00 in a report on Monday, December 9th. Royal Bank of Canada boosted their target price on Vertex Pharmaceuticals from $407.00 to $408.00 and gave the stock a “sector perform” rating in a research note on Thursday, February 20th. Piper Sandler reduced their target price on Vertex Pharmaceuticals from $535.00 to $533.00 and set an “overweight” rating for the company in a report on Monday, January 27th. Stifel Nicolaus lifted their price target on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a “hold” rating in a report on Monday, December 16th. Finally, Oppenheimer downgraded Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 19th. Ten investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $506.70.

Insider Activity

In related news, EVP David Altshuler sold 3,231 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the completion of the transaction, the executive vice president now owns 26,512 shares of the company’s stock, valued at approximately $13,256,000. The trade was a 10.86 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Ourania Tatsis sold 244 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $455.06, for a total transaction of $111,034.64. Following the sale, the executive vice president now directly owns 67,695 shares in the company, valued at $30,805,286.70. This trade represents a 0.36 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 4,315 shares of company stock worth $2,121,012 over the last ninety days. Company insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Trading Up 0.4 %

Shares of VRTX stock opened at $504.77 on Friday. The stock has a market capitalization of $129.62 billion, a price-to-earnings ratio of -229.44, a PEG ratio of 2.11 and a beta of 0.41. The company’s fifty day simple moving average is $457.74 and its two-hundred day simple moving average is $462.02. Vertex Pharmaceuticals Incorporated has a 1 year low of $377.85 and a 1 year high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. As a group, analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.